Non-small cell lung cancers (NSCLCs) carrying EGFR mutations are currently managed with TKIs, and tumor progression after treatment has been correlated with both genetic alterations and phenotypic transformations toward a mesenchymal phenotype [117]. This evidence concerns the gene EGFR and neoplasm.